Which MRD assay was used in the MD-01 trial?

Which MRD assay was used in the MD-01 trial?

• A. Signatera
• B. Guardant360
• C. CAPP-Seq
• D. Precise MRD

Answer: (D)

Detecting minimal residual disease relies on measuring tiny traces of tumor DNA in the blood after treatment. In the MD-01 trial, the MRD measurement was performed with Precise MRD, a tumor-informed assay designed to track patient-specific tumor mutations in circulating DNA. Because it is tailored to each patient’s tumor profile, it offers high sensitivity for detecting residual disease over time, which is crucial for longitudinal monitoring in trials. While other options are also used for MRD in different contexts, the trial documentation specifies Precise MRD as the assay employed, making it the correct choice.

Detecting minimal residual disease relies on measuring tiny traces of tumor DNA in the blood after treatment. In the MD-01 trial, the MRD measurement was performed with Precise MRD, a tumor-informed assay designed to track patient-specific tumor mutations in circulating DNA. Because it is tailored to each patient’s tumor profile, it offers high sensitivity for detecting residual disease over time, which is crucial for longitudinal monitoring in trials. While other options are also used for MRD in different contexts, the trial documentation specifies Precise MRD as the assay employed, making it the correct choice.